ZYN002

H.C. Wainwright & Co. believes that the current valuation of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has not taken into consideration the potential increased success rate of ZYN002 for epilepsy. Therefore, the firm believes the stock has the potential to deliver more than 60 percent upside...

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex. GW Pharma's strong gains helped boost shares of...